(Circulation. 1995;91:1450-1456.)
© 1995 American Heart Association, Inc.
Articles |
Increased Serum Concentrations of Procollagen Peptides in Essential Hypertension
Relation to Cardiac Alterations
From the Department of Internal Medicine (J.D.), Center for Biomedical Research, School of Medicine, University of Navarra, Pamplona, and the Department of Medicine (J.D.), School of Medicine, University of Zaragoza, Zaragoza; the Division of Medicine (C.L., G.M.), San Jorge General Hospital, Huesca; and the Department of Clinical Biochemistry (M.J.G., I.M.), University Clinic, School of Medicine, University of Navarra, Pamplona, Spain.
Correspondence to Javier Díez, MD, PhD, Unidad de Fisiopatologia Vascular, Dpto de Medicina Interna, Centro de Investigaciones Biomédicas, Facultad de Medicina, C/ Irunlarrea s/n, 31080 Pamplona, Spain.
 |
Abstract |
|---|
 Top Abstract IntroductionMethods Results Discussion References |
|---|
Background The serum concentrations of two procollagen-derived peptides, procollagen type III amino terminal peptide (PIIIP) and procollagen type I carboxy terminal peptide (PIP), have been proposed as useful markers of the tissue synthesis of collagen type III and type I, respectively. Therefore, this study was designed to evaluate fibrogenic activity in patients with essential hypertension by measuring serum PIIIP and PIP. Furthermore, since hypertensive heart disease is characterized by myocardial accumulation of collagen type III and type I, a second aim of the study was to assess whether some relation exists between the serum concentrations of PIIIP and PIP and several parameters of left ventricular anatomy and function in hypertensive patients.
Methods and Results The study was performed in 50 patients with never-treated essential hypertension and in 30 normotensive control subjects. Measurements were repeated in 43 hypertensive patients after 6 months of treatment with the angiotensin-converting enzyme inhibitor lisinopril. The serum concentrations of PIIIP and PIP were measured by specific radioimmunoassay. Two-dimensional, targeted M-mode and Doppler ultrasound recordings were obtained in every subject to determine several parameters of the left ventricle anatomy and function. Ambulatory ECG monitoring was performed in each patient, and the recorded ventricular arrhythmias were categorized according to Lown-Wolf classification. Baseline serum PIIIP and PIP were increased (P<.001) in hypertensive patients as compared with normotensive subjects. An inverse correlation was found between serum PIIIP and the ratio between maximal early transmitral flow velocity and maximal late transmitral flow velocity measured during diastole (r=-.3786, P<.01) in the group of hypertensive patients. Serum PIP was correlated directly with the left ventricular mass index (r=.3277, P<.05) in the group of hypertensive patients. Serum PIP concentrations increased in parallel with the increase in the grade of ventricular arrhythmias in the group of hypertensive patients. Treated patients attained normalization in blood pressure, amelioration of diastolic filling, regression of left ventricular mass index, and a diminution in the number of daily ventricular extrasystoles. In addition, serum PIIIP and PIP concentrations decreased significantly (P<.001) to normal values in patients treated with lisinopril.
Conclusions These findings suggest that tissue synthesis of collagen type III and type I is abnormally increased in essential hypertension and can be normalized by treatment with lisinopril. On the other hand, our results suggest that serum PIIIP and PIP are related to several anatomic and functional alterations of the hypertensive left ventricle. Serum procollagen peptide measurements may therefore provide indirect diagnostic information on the myocardial fibrosis associated with arterial hypertension.
Key Words: hypertension • hypertrophy • peptides
|
Introduction |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Besides myocyte hypertrophy, a disproportionate accumulation of fibrillar collagen type III and type I occurs within the normal connective tissue structures of the myocardial interstitium in the left ventricle of animals1 2 3 4 5 6 7 and humans8 9 10 11 12 with arterial hypertension. This reactive fibrosis is accomplished by alterations in collagen synthesis and degradation and by fibroblast proliferation.13 14 Hemodynamic loading, ischemia, hormones, and growth factors may participate in the development of myocardial fibrosis that occurs in hypertension.15 16 As shown experimentally3 17 and clinically,18 a rise in collagen content adversely raises myocardial stiffness and promotes abnormalities of cardiac function. In addition, it has been demonstrated that ventricular arrhythmias in hypertensive patients are related to the degree of myocardial fibrosis.19
Although cardiac biopsies are reliable for measuring myocardial fibrosis,10 11 18 20 it seems necessary to develop noninvasive methods that indicate the presence of myocardial fibrosis in hypertensive patients (that is, biochemical markers of collagen synthesis).
Collagen types III and I are synthesized as procollagens with a small amino terminal and a larger carboxy terminal propeptide. Once secreted into the extracellular space, the propeptides are removed by specific endopeptidases, thus allowing integration of the rigid collagen triple helix into the growing fibril.21 The three–amino acid procollagen type III amino terminal peptide (PIIIP) formed during this process is released into the blood. The serum concentration of PIIIP has been proposed as a useful marker of collagen type III synthesis.22 This is supported by a diversity of clinical observations demonstrating that high serum levels of the peptides reflect ongoing tissue fibrosis.23 24 25 26 27 In a preliminary study, we have shown that the serum concentration of PIIIP is abnormally increased in a small group of patients with essential hypertension,28 thus suggesting that collagen type III synthesis and fibril formation is also increased in this condition.
The 10–amino acid procollagen type I carboxy terminal peptide (PIP) is cleaved off procollagen type I during synthesis of the fibril forming collagen type I. In contrast to PIIIP, PIP is completely removed from its procollagen precursor during extracellular processing of collagen type I,21 thus offering the theoretical advantage of directly reflecting fibrogenesis. This has been confirmed in studies conducted in patients with different clinical conditions.29 30 31 Therefore, the serum concentrations of both PIP and PIIIP were measured in the present study to assess more accurately the intensity of the fibrogenic process in patients having essential hypertension. In addition, the relation between serum concentrations of the two peptides and several parameters of left ventricular anatomy and function were analyzed to delineate the value of these peptides as potential markers of ventricular fibrosis in the hypertensive patient.
|
Methods |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Subjects
The study population consisted of 50 patients with mild to moderate essential hypertension never treated and 30 normotensive control subjects. The hypertensive patients were not the same subjects studied in a previous publication.28 All subjects gave informed consent, and the local committee on human research approved the study protocol.
Arterial blood pressure was measured in the
morning, after 10
minutes in the supine position, using a mercury column
sphygmomanometer. The I and V phases of the Korotkoff sounds were used;
three measurements were obtained on each occasion, at 5-minute
intervals, and averaged. Arterial hypertension was said to be
present if the systolic blood pressure and diastolic blood pressure
were 
140 and 90 mm Hg, respectively. All patients had appropriate
clinical and laboratory evaluation to exclude hypertension secondary to
the following: renal disorders, renal artery abnormalities,
adrenocortical disorders, pheochromocytoma, and iatrogenic
causes.32 Conditions associated with elevated serum
concentrations of PIIIP (chronic liver disease, pulmonary fibrosis,
rheumatoid arthritis, extensive wounds, acute myocardial infarction) or
PIP (alcoholic liver disease, metabolic bone disease) were excluded
after complete medical examination. We also excluded patients with
overt coronary artery disease or other organic heart diseases as
evidenced by clinical, ECG, and echocardiographic criteria. None of the
women were pregnant or taking oral contraceptives.
Forty-three patients received lisinopril as treatment (range, 10 to 20 mg once daily) for 6 months. The therapeutic goal was to achieve a systolic blood pressure and diastolic blood pressure of <140 and 90 mm Hg, respectively. After the 6-month period of treatment, each patient underwent another complete medical examination.
The control group consisted of 30 subjects with blood pressure <140/90 mm Hg in repeated measurements. They were all healthy blood donors of the Center for Biomedical Research at the University of Navarra. None of the control subjects had echocardiographic evidence of cardiac disturbances.
Cardiac Studies
Echocardiographic Study
Two-dimensional, targeted M-mode and Doppler ultrasound
recordings were obtained in each patient. M-mode measurements were
taken according to the guidelines laid down by the American Society of
Echocardiography.33 Left ventricular mass was calculated
using the formula validated by Devereux and Reichek.34
Left ventricular mass index (LVMI) was obtained by dividing left
ventricular mass by body surface area. The relative wall thickness
(RWT) was measured at end diastole as the ratio of 2x (posterior wall
thickness/internal dimensions). The presence of left ventricular
hypertrophy was established either when LVMI was >111 g/m2
for men and >106 g/m2 for women or when RWT was
>0.44.35 Left ventricular fractional shortening and
ejection fraction were calculated according to Quinones et
al.36 The following pulsed Doppler measurements were
obtained37 : maximal early transmitral velocity in diastole
(VE) and maximal late transmitral velocity in diastole
(VA). The diagnosis of diastolic dysfunction was
established when the ratio of VE/VA was
<1.37
Ambulatory ECG Monitoring
All
ambulatory ECG tracings were recorded continuously during
one 24-hour period of monitoring with the use of portable
high-resolution ECG monitoring (Diagnostic Medical Instruments) at
baseline and 6 months thereafter. Standard recordings of two leads
corresponding to modified leads V1 and V5 were
recorded for analysis. The system was fully automated and
computerized using an Altair personal computer Holter system with
superimposition capability and with a record of <3% misinterpreted
ectopic complexes. Ventricular arrhythmias were categorized according
to the Lown-Wolf classification38 : grade 0, no premature
ventricular complexes; grade 1, <30 premature ventricular complexes
per hour; grade 2, >30 premature ventricular complexes per hour; grade
3, multiform; grade 4A, couplets; grade 4B, salvos (>3 consecutive
premature ventricular complexes at a rate >110 beats per minute); and
grade 5, R-on-T phenomenon.
All cardiac data were evaluated blind by one cardiologist without any knowledge of the biochemical data of the patient or the time sequence of the studies.
Biochemical Determinations
The general biochemical evaluation
included plasma glucose
concentration and serum lipid profile, measurement of serum potassium,
and serum and urine creatinine. Blood samples were drawn in fasting
condition. Biochemical parameters were measured by routine laboratory
methods. Renal clearance of creatinine was calculated as the product of
urine flow rate and the urine creatinine concentration divided by the
serum creatinine concentration.
Serum samples to determine PIIIP and PIP were taken at the time of the clinical studies and stored at -40°C for up to 6 months. The 6-month follow-up samples were analyzed together with samples from the initial setup. No changes were observed in the samples analyzed twice.
Serum PIIIP was determined by a coated-tube radioimmunoassay as described previously by Risteli et al,39 using commercial antisera specifically directed against the terminal amino terminal peptide (Behringwerke). The interassay and intra-assay variations for determining PIIIP were both <10%. The sensitivity (lower detection limit) was 1.5 ng of PIIIP/mL.
Serum PIP was determined by a rapid equilibrium radioimmunoassay according to the method by Meikko et al,40 using commercial antisera specifically directed against the terminal carboxy terminal peptide (Farmos Diagnostica). The interassay and intra-assay variations for determining PIP were 7% and 3%, respectively. The sensitivity (lower detection limit) was 1.2 µg of PIP/L.
Hormonal Determinations
Plasma renin activity (PRA) was
measured in resting conditions
by radioimmunoassay for angiotensin I (Sorin, Sallugia).41
The relation of PRA to the concurrent daily rate of urinary sodium
excretion was studied, and three major subgroups of patients were
defined according to the appropriateness or normality of the PRA in
relation to natriuresis as previously established41 : low
renin patients, normal renin patients, and high renin patients. Plasma
aldosterone concentration was determined by direct radioimmunoassay
(Abbott).41 Blood samples for both measurements were drawn
at 9:00 AM.
Statistical Studies
Values are expressed as mean±SEM.
A Student's t
test for unpaired data was used to assess the statistical significance
between control subjects and patients before treatment. A Student's
t test for paired data was used to assess the statistical
significance between patients before and after treatment. The
correlation between continuously distributed variables was tested by
univariate regression analysis.
|
Results |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Baseline Findings
The baseline demographic, biochemical, hormonal, and echocardiographic parameters are presented in Table 1
. As
expected, the levels of blood pressure were higher
in hypertensive patients as compared with normotensive patients. Heart
rate and body mass index were increased in hypertensive patients as
compared with normotensive patients. The creatinine clearance was
higher in the group of patients than in the group of control subjects.
Although values of plasma aldosterone were increased in hypertensive
patients as compared with normotensive patients, no biochemical
abnormalities suggestive of hyperaldosteronism (ie, hypokalemia) were
detected in the group of patients. No other differences in clinical,
biochemical, and hormonal parameters were found between the two groups
of subjects.
|
Although posterior wall thickness was increased in hypertensive patients as compared with normotensive patients, the calculated left ventricular mass and the LVMI were similar in the two groups of subjects. This could be due to the fact that the left ventricular internal dimensions and the body surface area were lower and higher, respectively, in hypertensive patients as compared with normotensive patients (data not shown). Left ventricular hypertrophy was present in 15 patients but in none of the normotensive subjects. The ratio between maximal early transmitral flow velocity and maximal late transmitral flow velocity measured during diastole was lesser in the group of hypertensive patients than in the group of normotensive patients. Diastolic dysfunction was diagnosed in 28 patients but in none of the normotensive patients. The parameters of systolic function were within the normal limits in all patients studied.
The Lown-Wolf
distribution of patients is presented in Table 2. There were no
episodes of ventricular fibrillation or
R-on-T phenomenon recorded. Mean ventricular ectopic activity was of
148±75 ventricular extrasystoles per day (range, 0 to 3077). No
relation was found between the presence or absence of left ventricular
hypertrophy and the severity or the number of ventricular arrhythmias
in hypertensive patients.
|
As shown in Fig 1, serum
concentrations of PIIIP and PIP
were higher (P<.001) in hypertensive patients than in
normotensive patients (PIIIP, 10.08±0.48 versus 8.47±0.77 ng/mL;
PIP,
139±6 versus 108±6 µg/L). Eleven hypertensive patients
exhibited
values of PIIIP above the upper end in normotensive patients (12.32
ng/mL). Eight hypertensive patients exhibited values of PIP above the
upper end in normotensive patients (170 µg/L in men and 202 µg/L in
women). In three hypertensive patients, the values of the two peptides
were above the upper ends measured in normotensive patients. No
significant clinical differences were found between patients with
abnormally high concentrations of either peptide and patients with
concentrations within the normal range.
|
An inverse correlation was
found between serum PIIIP and the ratio of
VE/VA (y=1.113-0.019x,
r=-.3786, P<.01) in the group of
hypertensive
patients (Fig 2). Serum PIP was correlated directly with
the left ventricular mass index
(y=67.068+0.198x,
r=.3277, P<.05) in the group of hypertensive
patients (Fig 3). No significant correlations were found
between PIIIP and LVMI or between PIP and VE/VA
in this study.
|
|
An association was found between serum PIP
concentrations and the
Lown-Wolf score of ventricular arrhythmias in hypertensive patients.
Serum PIP increased in parallel with the increase in the grade of
ventricular arrhythmias in hypertensive patients (Table 2
). No
association was found between serum PIIIP and the grade of ventricular
arrhythmias.
An association was found between the serum PIIIP
concentrations and the
appropriateness of PRA to the natriuresis in the group of hypertensive
patients (Table 3). The higher PIIIP concentrations were
found in high renin patients and the lower PIIIP concentrations in the
low renin patients, with intermediate PIIIP concentrations in normal
renin patients. No association was found between serum PIP and the
appropriateness of PRA to the natriuresis.
|
Findings After Treatment
As shown in Table 4,
arterial pressure was
normalized in patients receiving lisinopril. A significant decrease in
heart rate and body mass index was observed in treated patients.
Treatment with lisinopril was associated with the effective blockade of
the renin-angiotensin-aldosterone system, as assessed by the
significant increase in PRA and the significant decrease in plasma
aldosterone observed after treatment.
|
The values of echocardiographic
parameters assessing left ventricular
mass and dimensions were diminished after the treatment period (Table
5). Left ventricular hypertrophy regressed after
treatment in 7 of the 14 patients presenting this alteration before
treatment. The trend toward normalization of the ratio of
VE/VA did not attain statistical significance
(Table 5). Diastolic function was normalized with treatment in
6 of the
21 patients diagnosed of diastolic dysfunction before treatment. No
significant changes were observed in parameters related to systolic
function of the left ventricle after treatment with lisinopril (Table
5).
|
Patients on lisinopril attained ventricular ectopic activity reduction from 154±80 to 118±73 ventricular extrasystoles per day, but the difference did not reach statistical significance. The Lown-Wolf distribution of the patients after treatment was as follows: grade 0, 15; grade 1, 26; and grade 2, 2.
Serum PIIIP and PIP concentrations
were diminished (P<.001)
after 6 months of treatment with lisinopril (PIIIP, 10.06±0.49 versus
4.82±0.56 ng/mL; PIP, 140±7 versus 111±5 µg/L) (Fig
4). This was attributable to the decrease in serum PIIIP
and PIP concentrations in 41 and 32 of the patients treated with the
drug, respectively. Values of PIIIP or PIP above the upper end in
normotensive patients were present in 2 patients after treatment.
One of these patients exhibited abnormally high values of the two
peptides.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
In the first part of this study, we confirm our previous finding28 of increased serum concentrations of PIIIP in patients with essential hypertension. In addition, we show that serum concentrations of PIP are also abnormally increased in hypertensive patients. Both alterations are corrected after chronic treatment with the angiotensin-converting enzyme (ACE) inhibitor lisinopril.
As with PIIIP,42 PIP appears to be eliminated from the blood by the liver.40 Taking into account that none of the patients here studied showed altered hepatobiliary function, it can be proposed that elevated serum concentrations of PIIIP and PIP present in hypertensive patients represent an increased production of the two peptides.
Although serum PIIIP has been proposed as a useful marker of fibrogenesis,16 it should be noted that this peptide is not completely removed from its procollagen precursor during the extracellular processing of collagen type III.21 In contrast, the removal of PIP is complete, leading to fibril-forming collagen type I.21 This means that serum PIP reflects fibrogenesis more accurately than does serum PIIIP. Accordingly, the finding of elevated serum concentrations of PIP in essential hypertensive patients reinforces our previous suggestion28 that essential hypertension represents a clinical condition characterized by fibrogenic hyperactivity.
Hypertensive myocyte hypertrophy is believed to be primarily load based, whereas fibroblast activity appears to be primarily regulated by nonhemodynamic mechanisms.15 In this regard, we did observe that patients with high serum concentrations of PIIIP and PIP exhibited similar values of blood pressure and a similar time of exposure to hypertension than patients with normal serum concentrations. Therefore, the role of circulating substances in mediating collagen synthesis and fibrous tissue formation in hypertensive patients must be considered.
In vivo studies have shown that chronic elevations in circulating angiotensin II or aldosterone provoke myocardial accumulation of fibrillar collagen.43 In vitro, effector hormones of the renin-angiotensin-aldosterone system have been shown to directly enhance collagen synthesis of rat fibroblasts.44 45 Therefore, our findings of increased baseline aldosterone levels, the presence of an association between PRA and serum PIIIP and the decrease of serum PIIIP and PIP after blockade of the renin-angiotensin-aldosterone system with lisinopril—a drug that cannot interfere with the hepatobiliary elimination of peptides46 —add support to the involvement of angiotensin II and/or aldosterone in the exaggerated production of collagen in essential hypertensive patients. This possibility can be of particular interest when explaining the exaggerated synthesis of collagen type III, since we have reported previously that a direct correlation exists between serum PIIIP and PRA in hypertensive patients.28
In the second part of the study, we found that serum concentrations of PIIIP and PIP are related to the anatomic, diastolic, and electrical alterations that are characteristic of the hypertensive left ventricle.
A significant increase in fibrillar collagen content has been observed in the cardiac ventricles of both animals1 2 3 4 5 6 7 and humans8 9 10 11 12 with arterial hypertension. Therefore, it is tempting to speculate that increased serum concentrations of PIIIP and PIP present in hypertensive patients studied may reflect an increased ventricular synthesis of collagen types III and I. The observation that serum PIP correlates with left ventricular mass supports this possibility for collagen type I. However, because no cardiac biopsies were performed in this study, the cardiac origin of the two peptides remains speculative, and other extracardiac sources deserve to be considered. This is especially true for PIIIP, since collagen type III is also synthesized by cells of the vascular wall,47 and the collagen content of the arterial wall has been found to be increased in arterial hypertension.48 49 50 51
A diversity of experimental and clinical findings indicate that cardiac collagen accumulation adversely influences diastolic relaxation and stiffness of the left ventricle.3 17 18 On the other hand, in spontaneously hypertensive rats with left ventricular hypertrophy and fibrosis of the cardiac interstitium, lisinopril reversed fibrous tissue accumulation and restored myocardial stiffness.52 We have found that basal serum concentrations of PIIIP are inversely correlated with basal values of the ratio of VE/VA. This is in agreement with the previous observation that PIIIP correlates inversely with VE in hypertensive patients28 and suggests that myocardial accumulation of collagen type III plays a role in the impairment of diastolic function in patients with essential hypertension.
On the other hand, while the serum level of PIIIP was normalized after treatment with lisinopril, the ratio of VE/VA was not. We are aware that by measuring serum PIIIP, we assess the formation of collagen type III but not its degradation. It is likely that preexisting collagen is not removed during the 6-month treatment period, and this continues to influence adversely cardiac function.
Ventricular arrhythmias have been shown to occur more frequently in hypertensive patients with left ventricular hypertrophy than in those without.19 53 54 However, as previously reported by others,55 no differences in ectopic ventricular activity were observed in this study between patients with hypertrophy and patients without.
Alternatively, ventricular arrhythmias in hypertensive patients have been shown to be related to the degree of myocardial fibrosis.19 It has been proposed that myocardial fibrosis might favor ventricular reentry mechanisms by causing local variations in the activation-front conduction velocities.56 We did observe that an association exists between the baseline serum concentration of PIP and the Lown-Wolf grade of ventricular arrhythmias in hypertensive patients. Furthermore, the normalization of the serum concentrations of PIP after treatment was associated with improvement in the Lown-Wolf score of ventricular arrhythmias. Thus, it is tempting to speculate about the possibility that increased myocardial deposition of collagen type I promotes the appearance of alterations in electrical activity of the left ventricle in hypertensive patients.
Summary
The findings presented here show an increase of serum
concentrations of PIIIP and PIP in patients with essential
hypertension. Elevated serum PIIIP and PIP may be markers of increased
collagen type III and type I synthesis in these patients. The effects
of lisinopril on serum concentrations of the two peptides suggest that
the renin-angiotensin-aldosterone system may participate in the
excessive synthesis of collagen types III and I in hypertension. On the
other hand, the relations observed between serum PIIIP and PIP and
parameters of mass, diastolic function, and electrical activity of the
left ventricle permit us to propose that circulating
procollagen-derived peptides may reflect ongoing myocardial fibrosis in
essential hypertension.
Received July 5, 1994; revision received August 19, 1994; accepted September 23, 1994.
|
References |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
1. Doering CW, Jalil JE, Janicki JS, Pick R, Aghili S, Abrahams C, Weber KT. Collagen network remodeling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res. 1988;22:686-695. [Medline] [Order article via Infotrieve]
2. Michel JB, Salzmann JL, Carol ML, Dussaule JC, Azizi M, Corman B, Camilleri JP, Corvol P. Myocardial effect of converting enzyme inhibition in hypertensive and normotensive rats. Am J Med. 1988;84(suppl 3):A12-A21.
3.
Jalil JE, Doering CW, Janicki JS, Pick R, Clark WA, Weber KT.
Fibrillar collagen and myocardial stiffness in the intact hypertrophied
rat left ventricle. Circ Res. 1989;64:1041-1050.
4. Pfeffer JM, Pfeffer MA, Fishbein MC, Frohlich ED. Cardiac function and morphology with aging in the spontaneously hypertensive rat. Am J Physiol. 1979;6:H461-H468.
5. Pick R, Janicki JS, Weber KT. Myocardial fibrosis in nonhuman primate with pressure overload hypertrophy. Am J Pathol. 1989;135:771-781. [Abstract]
6.
Weber KT, Janicki JS, Pick R, Abrahams C, Shroff SG, Bashey
RI, Chen RM. Collagen in the hypertrophied pressure-overloaded
myocardium. Circulation. 1987;75:40-47.
7. Abrahams C, Janicki JS, Weber KT. Myocardial hypertrophy in Macaca fascicularis: structural remodeling of the collagen matrix. Lab Invest. 1987;56:676-683. [Medline] [Order article via Infotrieve]
8. Caspari PG, Newcomb M, Gibson K, Harris P. Collagen in the normal and hypertrophied human ventricle. Cardiovasc Res. 1977;11;554-558.
9. Anderson KR, St John Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol. 1979;128:79-85. [Medline] [Order article via Infotrieve]
10. Pearlman ES, Weber KT, Janicki JS, Pietra G, Fishman AP. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 1982;46:158-164. [Medline] [Order article via Infotrieve]
11. Huysman JAN, Vliegen HW, Vanderlaarse A, Eulderink F. Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophied human hearts. Pathol Res Pract. 1989;184:577-581. [Medline] [Order article via Infotrieve]
12. Pardo-Mindán FJ, Panizo A. Alterations in the extracellular matrix of the myocardium in essential hypertension. Eur Heart J. 1993;14(suppl J):12-14.
13. Weber KT, Eghbali M. Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy. Cardiovasc Rev Rep. 1991;12:61-69.
14. Eghbali M, Blumenfeld OO, Seifter S, Buttrick PM, Leinwand LA, Robinson TF, Zern MA, Giambrone MA. Localization of types I, III, and IV collagen mRNAs in rat heart cells by in situ hybridization. J Mol Cell Cardiol. 1989;21:103-113. [Medline] [Order article via Infotrieve]
15. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension. 1994;23(part 2):869-877.
16. Fujita M, Mikunija A, McUown DP, Franklin D. Regional myocardial volume alterations induced by brief repeated coronary occlusion in conscious dogs. J Am Coll Cardiol. 1988;12:1048-1053. [Abstract]
17. Thiedemann KU, Holubarsch C, Medugorac I, Jacob R. Connective tissue content and myocardial stiffness in pressure overload hypertrophy: a combined study of morphologic, morphometric, biochemical and mechanical parameters. Basic Res Cardiol. 1983;78:140-155. [Medline] [Order article via Infotrieve]
18.
Hess OM, Schneider J, Kock R, Bamert C, Grimm J, Krayenbuehl
HP. Diastolic function and myocardial structure in patients with
myocardial hypertrophy. Circulation. 1981;63:360-371.
19. McLenachan JM, Dargie HJ. Ventricular arrhythmias in hypertensive left ventricular hypertrophy: relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens. 1990;3:735-740. [Medline] [Order article via Infotrieve]
20. Villari B, Campbell SE, Hess OM, Mall G, Vassalli G, Weber KT, Krayenbuehl HP. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol. 1993;22:1477-1484. [Abstract]
21. Nimni ME. Fibrillar collagens: their byosynthesis, molecular structure, and mode of assembly. In: Zern MA, Reid LM, eds. Extracellular Matrix. New York, NY: Marcel Dekker; 1993:121-148.
22. Risteli L, Risteli J. Noninvasive methods for detection of organ fibrosis. In: Rojkind M, ed. Focus on Connective Tissue in Health and Disease. Boca Raton, Fla: CRC Press; 1990;61-98.
23. Trinchet JC, Hartmann DJ, Pateron D, Laarif M, Callard P, Ville G, Beaugrand M. Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis: relationship to liver histology and conventional liver tests. J Hepatol. 1991;12:139-144. [Medline] [Order article via Infotrieve]
24. Low RB, Cutroneo KR, Davis GS, Giancola MS. Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis. Lab Invest. 1983;48:755-759. [Medline] [Order article via Infotrieve]
25. Horslev-Petersen K, Bentsen K, Junker P, Lorenzen I. Serum aminoterminal type III procollagen peptide in rheumatoid arthritis. Arthritis Rheum. 1986;29:592-599. [Medline] [Order article via Infotrieve]
26. Bentsen KD, Lanng C, Horslev-Petersen K, Risteli J. The aminoterminal propeptide of type III procollagen and basement membrane components in serum during wound healing in man. Acta Chir Scand. 1988;154:97-101. [Medline] [Order article via Infotrieve]
27.
Thorbjorn Jensen L, Horslev-Petersen K, Toft P, Bentsen KD,
Grande P, Simonsen EE, Lorenzen I. Serum aminoterminal type III
procollagen peptide reflects repair after acute myocardial infarction.
Circulation. 1990;81:52-57.
28. Laviades C, Mayor G, Díez J. Treatment with lisinopril normalizes serum concentrations of procollagen type III amino-terminal peptide in patients with essential hypertension. Am J Hypertens. 1994;7:52-58. [Medline] [Order article via Infotrieve]
29. Schuppan D. Connective tissue polypeptides in serum as parameters to monitor antifibrotic treatment in hepatic fibrogenesis. J Hepatol. 1991;13(suppl 3):S17-S25.
30. Savolainen ER, Goldberg B, Leo MA, Velez M, Lieber CS. Diagnostic value of serum procollagen peptide measurements in alcoholic liver disease. Alcohol Clin Exp Res. 1984;8:384-389. [Medline] [Order article via Infotrieve]
31. Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as marker of collagen biosynthesis in bone: correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res. 1987;2:427-436. [Medline] [Order article via Infotrieve]
32. Müller FB, Laragh JH. Clinical evaluation and diferential diagnosis of the individual hypertensive patient. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press; 1990:1385-1396.
33.
Sahn DJ, DeMaría A, Kisslo J, Weyman A.
Recommendations regarding quantitation in M-mode echocardiography:
results of a survey of echocardiographic measurements.
Circulation. 1978;58:1072-1083.
34.
Devereux RB, Reichek N. Echocardiographic determination of
left ventricular mass in man: anatomic validation of the method.
Circulation. 1977;55:613-618.
35. Ganau A, Devereux RB, Roman MJ, De Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-1558. [Abstract]
36.
Quinones MA, Pickering E, Alexander JK. Percentage of
shortening of the echocardiographic left ventricular dimension: its use
in determining ejection fraction and stroke volume. Chest. 1978;74:59-65.
37. Nishimura RA, Abel MD, Hatle LK, Tajik AJ. Assessment of diastolic function of the heart: background and current application of Doppler echocardiography, II: clinical studies. Mayo Clin Proc. 1989;64:181-204. [Medline] [Order article via Infotrieve]
38. Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation. 1971;46:130-142.
39.
Risteli J, Niemi S, Trivedi P, Mäentausta O, Mowat AP,
Risteli L. Rapid equilibrium radioimmunoassay for the aminoterminal
propeptide of human type III procollagen. Clin Chem. 1988;34:715-718.
40.
Meikko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of
the carboxyterminal propeptide of human type I procollagen. Clin
Chem. 1990;36:1328-1332.
41. Brunner HR, Laragh JH, Baer L, Cragoe EJ Jr. Essential hypertension, renin, aldosterone, and heart attack and stroke. N Engl J Med. 1972;286:441-449.
42. Raedsch R, Stiehl A, Sieg A, Walther S, Kommerell B. Biliary excretion of procollagen type III peptide in healthy humans and in patients with alcoholic cirrhosis of the liver. Gastroenterology. 1983;85:1265-1270. [Medline] [Order article via Infotrieve]
43. Sun Y, Ratajska A, Zhou G, Weber KT. Angiotensin converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med. 1993;122:395-403. [Medline] [Order article via Infotrieve]
44.
Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH.
Identification of functional angiotensin II receptors on rat cardiac
fibroblasts. Circulation. 1993;88:2849-2861.
45. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820. [Medline] [Order article via Infotrieve]
46. Beerman B, Till AE, Gomez HJ, Hichens M, Bolognese JA, Junggren I. Pharmacokinetics of lisinopril (i.v./p.o.) in healthy volunteers. Biopharm Drug Dispos. 1989;10:397-409. [Medline] [Order article via Infotrieve]
47. Burgeson RE. New collagens, new concepts. Annu Rev Cell Biol. 1988;4:551-577.
48.
Ooshima A, Fuller GC, Cardinale GJ, Spector S, Udenfriend S.
Increased collagen synthesis in blood vessels of hypertensive rats and
its reversal by antihypertensive agents. Proc Natl Acad Sci
U S A. 1974;71:3019-3023.
49.
Brecher P, Chan CT, Franzblau C, Faris B, Chobanian AV.
Effects of hypertension and its reversal on aortic metabolism in the
rat. Circ Res. 1978;43:561-569.
50. Gilligan JP, Spector S. Synthesis of collagen in cardiac and vascular walls. Hypertension. 1984;6(suppl III):III-44-III-49.
51.
Albadalejo P, Bouaziz H, Duriez M, Gohlke P, Levy BI, Safar
ME, Benetos A. Angiotensin-converting enzyme inhibition prevents the
increase in aortic collagen in rats. Hypertension. 1994;23:74-82.
52.
Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of
lisinopril in rats with genetic hypertension and left ventricular
hypertrophy. Circulation. 1991;83:1771-1779.
53. Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. Hypertension and sudden death: increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med. 1984;77:18-22. [Medline] [Order article via Infotrieve]
54. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med. 1987;317:787-792. [Abstract]
55. Papademetriou V, Price M, Notargiacoma A, Gottdiener J, Fletcher RD, Freis ED. Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy. Am Heart J. 1985;110:595-599. [Medline] [Order article via Infotrieve]
56. Cameron JS, Myerburg RJ, Wong SS, Gaide MS, Epstein K, Alvarez TR, Gelband H, Guse PA, Basset AL. Electrophysiologic consequences of chronic experimentally induced left ventricular pressure overload. J Am Coll Cardiol. 1983;2:481-487.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  G. J. Mak, M. T. Ledwidge, C. J. Watson, D. M. Phelan, I. R. Dawkins, N. F. Murphy, A. K. Patle, J. A. Baugh, and K. M. McDonald Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1674 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dhingra, M. J. Pencina, P. Schrader, T. J. Wang, D. Levy, K. Pencina, D. A. Siwik, W. S. Colucci, E. J. Benjamin, and R. S. Vasan Relations of Matrix Remodeling Biomarkers to Blood Pressure Progression and Incidence of Hypertension in the Community Circulation, March 3, 2009; 119(8): 1101 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gonzalez, B. Lopez, S. Ravassa, J. Beaumont, T. Arias, N. Hermida, A. Zudaire, and J. Diez Biochemical markers of myocardial remodelling in hypertensive heart disease Cardiovasc Res, February 15, 2009; 81(3): 509 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lopez, A. Gonzalez, J. Beaumont, R. Querejeta, M. Larman, and J. Diez Identification of a Potential Cardiac Antifibrotic Mechanism of Torasemide in Patients With Chronic Heart Failure J. Am. Coll. Cardiol., August 28, 2007; 50(9): 859 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M M. Lindsay and F. G Dunn Biochemical evidence of myocardial fibrosis in veteran endurance athletes Br. J. Sports Med., July 1, 2007; 41(7): 447 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C Shah, S. Pringle, and A. Struthers Aldosterone Blockade Over and Above ACE-Inhibitors in Patients with Coronary Artery Disease but without Heart Failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1): 20 - 30. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Alla, A. Kearney-Schwartz, A. Radauceanu, S. D. Dores, B. Dousset, and F. Zannad Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes Eur J Heart Fail, March 1, 2006; 8(2): 147 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cuspidi, M. Ciulla, and A. Zanchetti Hypertensive myocardial fibrosis Nephrol. Dial. Transplant., January 1, 2006; 21(1): 20 - 23. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zakynthinos, Ch. Pierrutsakos, Z. Daniil, and D. Papadogiannis Losartan Controlled Blood Pressure and Reduced Left Ventricular Hypertrophy But Did Not Alter Arrhythmias in Hypertensive Men with Preserved Systolic Function Angiology, July 1, 2005; 56(4): 439 - 449. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. Deschamps, K. A. Apple, A. H. Leonardi, J. E. McLean, W. M. Yarbrough, R. E. Stroud, L. L. Clark, J. A. Sample, and F. G. Spinale Myocardial Interstitial Matrix Metalloproteinase Activity Is Altered by Mechanical Changes in LV Load: Interaction With the Angiotensin Type 1 Receptor Circ. Res., May 27, 2005; 96(10): 1110 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Querejeta, B. Lopez, A. Gonzalez, E. Sanchez, M. Larman, J. L. Martinez Ubago, and J. Diez Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin: Relation to Myocardial Fibrosis Circulation, September 7, 2004; 110(10): 1263 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Ciulla, R. Paliotti, A. Esposito, J. Diez, B. Lopez, B. Dahlof, M. G. Nicholls, R. D. Smith, L. Gilles, F. Magrini, et al. Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis: Results of a Randomized Trial Circulation, August 3, 2004; 110(5): 552 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ahn, J. Varagic, M. Slama, D. Susic, and E. D. Frohlich Cardiac structural and functional responses to salt loading in SHR Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H767 - H772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lopez, R. Querejeta, A. Gonzalez, E. Sanchez, M. Larman, and J. Diez Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure J. Am. Coll. Cardiol., June 2, 2004; 43(11): 2028 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Grandi, D. Imperiale, R. Santillo, E. Barlocco, A. Bertolini, L. Guasti, and A. Venco Aldosterone Antagonist Improves Diastolic Function in Essential Hypertension Hypertension, November 1, 2002; 40(5): 647 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Maceira, J. Barba, O. Beloqui, and J. Diez Ultrasonic Backscatter and Diastolic Function in Hypertensive Patients Hypertension, September 1, 2002; 40(3): 239 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Lindsay, P. Maxwell, and F. G. Dunn TIMP-1: A Marker of Left Ventricular Diastolic Dysfunction and Fibrosis in Hypertension Hypertension, August 1, 2002; 40(2): 136 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Diez, R. Querejeta, B. Lopez, A. Gonzalez, M. Larman, and J. L. Martinez Ubago Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients Circulation, May 28, 2002; 105(21): 2512 - 2517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Maceira, J. Barba, N. Varo, O. Beloqui, and J. Diez Ultrasonic Backscatter and Serum Marker of Cardiac Fibrosis in Hypertensives Hypertension, April 1, 2002; 39(4): 923 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gonzalez, B. Lopez, S. Ravassa, R. Querejeta, M. Larman, J. Diez, and M. A. Fortuno Stimulation of Cardiac Apoptosis in Essential Hypertension: Potential Role of Angiotensin II Hypertension, January 1, 2002; 39(1): 75 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. T. Weber Aldosterone in Congestive Heart Failure N. Engl. J. Med., December 6, 2001; 345(23): 1689 - 1697. [Full Text] [PDF]
|
|
|
|
|
|
A. D Struthers Review: Aldosterone-induced vasculopathy: a new reversible cause of cardiac death Journal of Renin-Angiotensin-Aldosterone System, December 1, 2001; 2(4): 211 - 214. [PDF]
|
|
|
|
|
|
B. Lopez, A. Gonzalez, N. Varo, C. Laviades, R. Querejeta, and J. Diez Biochemical Assessment of Myocardial Fibrosis in Hypertensive Heart Disease Hypertension, November 1, 2001; 38(5): 1222 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zannad, B. Dousset, and F. Alla Treatment of Congestive Heart Failure: Interfering the Aldosterone-Cardiac Extracellular Matrix Relationship Hypertension, November 1, 2001; 38(5): 1227 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Intengan and E. L. Schiffrin Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis Hypertension, September 1, 2001; 38(3): 581 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Weber Cardioreparation in Hypertensive Heart Disease Hypertension, September 1, 2001; 38(3): 588 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lopez, R. Querejeta, N. Varo, A. Gonzalez, M. Larman, J. L. Martinez Ubago, and J. Diez Usefulness of Serum Carboxy-Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive Patients Circulation, July 17, 2001; 104(3): 286 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. M. Pinto, S.-J. Pinto-Sietsma, T. Philipp, S. Engler, P. Ko{beta}mehl, B. Hocher, H. Marquardt, S. Sethmann, R. Lauster, H.-J. Merker, et al. Reduction in Left Ventricular Messenger RNA for Transforming Growth Factor {beta}1 Attenuates Left Ventricular Fibrosis and Improves Survival Without Lowering Blood Pressure in the Hypertensive TGR(mRen2)27 Rat Hypertension, November 1, 2000; 36(5): 747 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Laviades, N. Varo, and J. Diez Transforming Growth Factor {beta} in Hypertensives With Cardiorenal Damage Hypertension, October 1, 2000; 36(4): 517 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Weber Targeting Pathological Remodeling : Concepts of Cardioprotection and Reparation Circulation, September 19, 2000; 102(12): 1342 - 1345. [Full Text] [PDF]
|
|
|
|
|
|
C. G. Brilla, R. C. Funck, and H. Rupp Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease Circulation, September 19, 2000; 102(12): 1388 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Intengan and E. L. Schiffrin Structure and Mechanical Properties of Resistance Arteries in Hypertension : Role of Adhesion Molecules and Extracellular Matrix Determinants Hypertension, September 1, 2000; 36(3): 312 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. O'Callaghan and B. Williams Mechanical Strain-Induced Extracellular Matrix Production by Human Vascular Smooth Muscle Cells : Role of TGF-{beta}1 Hypertension, September 1, 2000; 36(3): 319 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G Spinale, M. L Coker, B. R Bond, and J. L Zellner Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target Cardiovasc Res, May 1, 2000; 46(2): 225 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G Brilla Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs Cardiovasc Res, May 1, 2000; 46(2): 324 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Querejeta, N. Varo, B. Lopez, M. Larman, E. Artinano, J. C. Etayo, J. L. M. Ubago, M. Gutierrez-Stampa, J. I. Emparanza, M. J. Gil, et al. Serum Carboxy-Terminal Propeptide of Procollagen Type I Is a Marker of Myocardial Fibrosis in Hypertensive Heart Disease Circulation, April 11, 2000; 101(14): 1729 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Wallace, R. C. Cuneo, P. A. Lundberg, T. Rosén, J. O. L. Jørgensen, S. Longobardi, N. Keay, L. Sacca, J. S. Christiansen, B.-A. Bengtsson, et al. Responses of Markers of Bone and Collagen Turnover to Exercise, Growth Hormone (GH) Administration, and GH Withdrawal in Trained Adult Males J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 124 - 133. [Abstract] [Full Text]
|
|
|
|
|
|
E. D. Frohlich Risk Mechanisms in Hypertensive Heart Disease Hypertension, October 1, 1999; 34(4): 782 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Weber Monitoring Vascular Sclerosis in Hypertension : A New Window of Opportunity Circulation, August 11, 1998; 98(6): 498 - 500. [Full Text] [PDF]
|
|
|
|
|
|
C. Laviades, N. Varo, J. Fernandez, G. Mayor, M. J. Gil, I. Monreal, and J. Diez Abnormalities of the Extracellular Degradation of Collagen Type I in Essential Hypertension Circulation, August 11, 1998; 98(6): 535 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sato, K. Kataoka, A. Matsumori, S. Sasayama, T. Yamada, H. Ito, and Y. Takatsu Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy Heart, November 1, 1997; 78(5): 505 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Uusimaa, J. Risteli, M. Niemela, J. Lumme, M. Ikaheimo, A. Jounela, and K. Peuhkurinen Collagen Scar Formation After Acute Myocardial Infarction : Relationships to Infarct Size, Left Ventricular Function, and Coronary Artery Patency Circulation, October 21, 1997; 96(8): 2565 - 2572. [Abstract] [Full Text]
|
|
|
|
|
|
J. Dieez and C. Laviades Monitoring fibrillar collagen turnover in hypertensive heart disease Cardiovasc Res, August 1, 1997; 35(2): 202 - 205. [Full Text] [PDF]
|
|
|
|
|
|
R. J MacFadyen, C. S Barr, and A. D Struthers Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients Cardiovasc Res, July 1, 1997; 35(1): 30 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. Jensen and N. B. Host Collagen: scaffold for repair or execution Cardiovasc Res, March 1, 1997; 33(3): 535 - 539. [PDF]
|
|
|
|
|
|
J. Diez, A. Panizo, M. J. Gil, I. Monreal, M. Hernandez, and J. P. Mindan Serum Markers of Collagen Type I Metabolism in Spontaneously Hypertensive Rats : Relation to Myocardial Fibrosis Circulation, March 1, 1996; 93(5): 1026 - 1032. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||